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PLINICAL RESEARCH Clinical Trial
ral Rapamycin After Coronary
are-Metal Stent Implantation to Prevent Restenosis
he Prospective, Randomized Oral
apamycin in Argentina (ORAR II) Study
lfredo E. Rodriguez, MD, PHD, FACC,* Juan F. Granada, MD,† Máximo Rodriguez-Alemparte, MD,*
esar F. Vigo, MD,* Juan Delgado, MD,† Carlos Fernandez-Pereira, MD,* Antonio Pocovi, MD,*
lfredo M. Rodriguez-Granillo, BS,* Daryl Schulz, RTN,† Albert E. Raizner, MD, FACC,†
gor Palacios, MD, FACC,‡ William O’Neill, MD, FACC,§ Grzegorz L. Kaluza, MD, PHD,†
regg Stone, MD, PHD, FACC, for the ORAR II Investigators
uenos Aires, Argentina; Houston, Texas; Boston, Massachusetts; Royal Oak, Michigan; and New York, New York
OBJECTIVES The purpose of this study was to assess the role of oral rapamycin in decreased restenosis after
bare metal stent implantation.
BACKGROUND Small observational studies suggest that the administration of oral rapamycin reduces
angiographic restenosis after bare metal stent implantation.
METHODS Between September 2003 and September 2004, 100 patients were randomized to either oral
rapamycin (6-mg loading dose given 2.7 h before intervention followed by 3 mg/day for 14
days) plus diltiazem 180 mg/day or no therapy after the implantation of a coronary bare metal
stent design. The primary study end point was incidence of angiographic binary restenosis and
late loss at nine months. The secondary end points were target lesion revascularization, target
vessel revascularization, and incidence of major adverse cardiovascular events at 1 year.
RESULTS Angiographic follow-up was completed in 87% of patients. In the rapamycin group, the drug
was well tolerated (26% minor side effects) and was maintained in 96% of patients. At 9
months, the in-segment binary restenosis was reduced by 72% (11.6% rapamycin vs. 42.8%
no-therapy group, p  0.001) and the in-stent binary restenosis was reduced by 65% (12%
rapamycin vs. 34.6% no-therapy group, p  0.009). The in-segment late loss was also
significantly reduced with oral therapy (0.66 vs. 1.13 mm, respectively; 43% reduction, p 
0.001). At 1 year, patients in the oral rapamycin group also showed a significantly lower
incidence of target vessel revascularization (8.3% vs. 38%, respectively, p  0.001), target
lesion revascularization (7.6% vs. 37.2%, respectively, p  0.001), and major adverse
cardiovascular events (20% vs. 44%, respectively, p  0.018).
CONCLUSIONS This randomized, controlled, and unblinded study showed that the administration of oral
rapamycin during 14 days after stent implantation significantly reduces angiographic and
clinical parameters of restenosis. (J Am Coll Cardiol 2006;47:1522–9) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.052American College of Cardiology Foundation
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rince the introduction of coronary angioplasty, restenosis of
he target lesion has been the main limitation of this
rocedure. Acute vessel recoil, chronic remodeling, and
ntimal hyperplasia are the mechanisms involved in this
rocess (1–4). However, after the introduction of stents in
aily practice during interventional procedures, intimal
yperplasia became the mechanism associated with the
athophysiology of in-stent restenosis (5–9). Therefore, its
revention should be related to therapies that inhibit
mooth muscle cell proliferation.
In recent years, drug-eluting stents (sirolimus, Johnson &
ohnson, Miami Lakes, Florida; and paclitaxel, Boston
From the *Otamendi Hospital, Buenos Aires, Argentina; †The Methodist Hospital
esearch Institute, Houston, Texas; ‡Massachusetts General Hospital, Boston,
assachusetts; §William Beaumont Hospital, Royal Oak, Michigan; and Columbia
niversity, New York, New York. Dr. Delgado is now affiliated with the Corbic
esearch Foundation, Envigado, Columbia.s
Manuscript received October 21, 2005; revised manuscript received November 24,
005, accepted December 13, 2005.cientific, Natick, Massachusetts) have been associated with
ignificant reduction of in-stent restenosis (10–17). Al-
hough clinical and angiographic parameters of restenosis
ere significantly improved, long-term safety data of these
tents needs to be addressed (18,19). Sirolimus (Rapamune,
yeth, Roses Point, New York) is a potent immunosup-
ressive and antiproliferative agent that was approved by the
.S. Food and Drug Administration for use in patients after
enal transplantation (20–24). Systemic use of rapamycin
nd its analog were associated in animal data with a
ignificant reduction of intimal hyperplasia (22–25), but
nly recently were clinical studies with oral administration
eported (26–31).
The purpose of the present controlled, randomized study
as carried out to determine whether short oral adminis-
ration of the drug was associated with a reduction of
estenosis in patients treated percutaneously with bare metal
tent therapy of de novo lesions.
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atient population and study design. From September
003 to September 2004, 100 patients with severe stenosis
n de novo coronary arteries were enrolled and included in
his protocol. All of the percutaneous coronary interventions
PCIs) were performed at the Catheterization Laboratories
t Otamendi Hospital and Sanatorio Las Lomas in Buenos
ires, Argentina. For a list of study participants, please see
he Appendix.
Patients were considered for randomization if they meet
he following criteria: clinical indication of percutaneous
oronary revascularization, age 18 years, de novo severe
tenosis in a native coronary artery, lesion suitable for stent,
eference vessel size between 2.5 and 4.0 by visual estima-
ion, and candidate for coronary bypass surgery. Enrollment
as also permitted after the successful treatment of one
dditional non-study lesion in a non-study vessel before
andomization.
Patients were excluded if they had acute myocardial
nfarction 48 h before randomization, rapamycin allergy,
lopidogrel or aspirin intolerance, significant bleeding in the
ast 6 months, stroke or transient ischemic attack in the last
2 months, severe concomitant illness, recent major bleed-
ng requiring transfusion, major blood dyscrasias, partici-
ation in another trial that did not allow a follow-up
ngiogram, hyperlipidemia of difficult treatment, thrombo-
ytopenic disease, or chronic total occlusion or in-stent
estenosis lesions, or if they were not amenable to signing the
nformed consent form allowing a follow-up angiogram.
esion length was not an exclusion criteria, and multiple
tents in the same vessel as well as overlapping stents were
llowed.
The protocol of this non–industry-sponsor study was
pproved by the ethics committee of the participating
enters of the study, by the ethics committee of the
rgentine Society of Cardiac Angiography and Interven-
ions, and by the Argentina National Regulatory Agency for
rug, Food, and Medical Technology. During the study, an
ndependent Safety Monitoring Committee adjudicated the
linical adverse events. The study was conducted according
o the principles of the Declaration of Helsinki, and all
atients signed a written inform consent form for partici-
ation in this trial.
andomization, medication, and coronary procedures. All
ligible patients were randomized in the catheterization
aboratory, immediately after the diagnostic angiogram was
erformed, to either the control group or the oral rapamycin
Abbreviations and Acronyms
MACE  major adverse cardiovascular event
PCI  percutaneous coronary intervention
TLR  target lesion revascularization
TVR  target vessel revascularizationroup. The randomization process in each center was berformed in a blinded manner for the coordinating center
ith the use of an Internet system containing the block
andomization sequence for each participating center. In the
ral rapamycin arm, patients received a loading dose of 6 mg
t 2.71  0.9 h before stent implantation, followed by 3
g/day for a total of 14 days. Sustained-release diltiazem
80 mg/day was added to the sirolimus regimen to achieve
igher sirolimus blood concentrations (21). Patients in the
ontrol group did not receive either a placebo or additional
herapy. Blood samples were drawn to measure sirolimus
lood levels and were taken at seven days after an oral
oading dose of sirolimus in a central core laboratory
27,31). In addition, serum creatine, cholesterol, triglycer-
des, red and white blood cells, and platelet counts were
easured before and at the end of sirolimus treatment. A
linical interview was required each week for the first month
f treatment, then monthly for six months, and at one year
fter the intervention. Coronary angiography was scheduled
etween six to nine months after the initial PCI procedure.
CI and stent procedure. The PCI was performed using
tandard techniques described elsewhere (27). All 100
atients received one or more identical closed-cell stent
esign; an appropriate-sized stent (Gryphus stent delivery
ystem, Endovascular Devices Inc., Wilmington, Delaware)
ith a ratio of stent diameter to distal reference vessel
iameter of 1:1 to 1.1:1 was implanted at a pressure of at
east 13 atm guided by on-line quantitative coronary an-
iography. The stent used in this study is a CE-marked,
linically tested, closed-cell design with a strut thickness and
idth of 110 m and 120 m, respectively. The same stent
esign was used to avoid potential bias with stent selection
n both groups (32). The available stent lengths were 15, 18,
nd 23 mm, and the stent diameters were 2.5, 3.0, 3.5, and
.0 mm. All patients received 325 mg/day of aspirin
ndefinitely, and clopidogrel at a loading dose of 300 mg on
he day of the procedure and 75 mg/day thereafter for one
onth. Statins were given to all patients indefinitely.
tudy end points. The primary end point of the study was
o compare the angiographic binary restenosis rate and late
oss determined by an independent core laboratory blinded
o treatment allocation. Angiographic binary restenosis was
efined as 50% residual stenosis in the target lesion in the
ollow-up angiography. In patients with multiple lesions,
he lesions were counted separately. Secondary end points
ere target lesion revascularization (TLR), target vessel
evascularization (TVR), target vessel failure, and major
dverse cardiovascular events (MACEs). The TLR and
VR were performed in the presence of angiographic
estenosis and symptoms and signs of myocardial ischemia,
etermined by an independent clinical events committee
clinically driven). A MACE was defined as death, myocar-
ial infarction, stroke, and TVR at 1 year of follow-up.
arget vessel failure was defined as death, non-fatal myo-
ardial infarction, and TVR during the entire follow-up
eriod. The TLR was counted by lesion, TVR was counted
y vessel, and MACEs were counted by patient. The
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Oral Rapamycin After Bare-Metal Stent Therapy April 18, 2006:1522–9iagnosis of acute myocardial infarction was based on
ypical chest pain combined with either new pathological Q
aves or an increase of creatine kinase to 3 times the
pper limit of normal, with a concomitant increase in the
B isoenzyme. Sirolimus compliance and adverse side
ffects related to oral administration of sirolimus were also
ecorded. All events were adjudicated by an independent
linical events committee whose members were unaware of
he patient’s assigned treatment.
uantitative coronary angiography. Angiographies were
nalyzed in all patients at the angiographic core laboratory
acilities of the Methodist Research Institute, Houston,
exas, by blinded operators, using an automatic edge
etection system (CAASII Pie Medical Imaging, Maas-
rich, the Netherlands). The analysis segment comprised the
tent segment and the proximal and distal stent edge,
efined as 5 mm proximal or distal to the stent. Similar
iews (an average of two orthogonal projections) were
elected for angiograms recorded before the intervention,
mmediately after stent deployment, and at follow-up. Each
ngiography sequence was preceded by an intracoronary
njection of nitroglycerin. Acute gain was defined as the
ifference between minimal luminal diameter before and at
he end of the PCIs and stent procedure. Late lumen loss
as calculated as the difference in minimal luminal diameter
etween measurements noted immediately after the proce-
ure and at follow-up. Net gain was defined as the differ-
nces between minimal luminal diameter at follow-up and
efore the interventional procedure.
Table 1. Baseline Demographic, Clinical, and
Characteristics
Oral Sirolim
Stent Gro
Age (yrs) 64.6
Male gender (%) 8
Diabetes mellitus (%) 2
Hyperlipidemia (%)* 9
Hypertension (%) 9
Current smoker (%) 2
Previous myocardial infarction (%) 2
Non–Q-wave type
Q-wave type 2
Stable angina
Unstable angina† 7
Target artery (%)
Right coronary artery 2
Left anterior descending artery 5
Left circumflex coronary artery 2
Left main
Multiple-vessel disease 8
ACC/AHA class (%)
A
B1 2
B2 4
C 2
Multilesion PCI (%) 3
Plus-minus values are means  SD. *Hyperlipidemia was defi
(3.4 mmol/l); †unstable angina was defined according to Braunwal
ACC American College of Cardiology; AHA American Htatistical analysis. The sample size of the study was
etermined on the basis of a test for a trend analysis based
n the estimation for the primary end point of angiographic
estenosis and late loss according to our previous pilot trials
nd from recent trials with drug-eluting stents; in the
ontrol group we assumed an incidence of binary restenosis
f 35% in accordance with recently reported data (12–
4,16,17) of in-segment restenosis with bare metal stents. If
e average the restenosis rate in the control arm of those
rug-eluting stents trials, the in-segment restenosis rate was
ver 35%. In the oral rapamycin group, we assumed a binary
estenosis rate of 10% according our previous pilot studies
27,31). Using a two-sided test for differences in indepen-
ent binomial proportions with an alpha level of 0.05, we
alculated that 80 patients (40 for each group) would have to
ndergo randomization for the study to have 80% power to
etect a difference in the binary restenosis rate among both
roups; thus, we enrolled a total of 50 patients in each arm
o accommodate patients in whom follow-up angiography
ould not be performed. Late loss was calculated assuming
loss around 0.60 mm in the rapamycin group and 1.10 mm
n the control arm, which is in accordance with the late loss
ata obtained in our previous pilots trials with oral rapamy-
in (27,31). With the above number, we needed a sample
ize of 30 patients in each group for a power of 0.80%.
Continuous variables were compared using an unpaired
wo-sided Student t test, and categorical variables were
ompared using the Fisher exact test. Continuous variables
ere expressed as mean  SD, and categorical variables
ographic Characteristics
Standard
 50)
Control Standard
Stent Group (n  50) p Value
65.1  8.3 0.775
94 0.945
8 0.054
92 0.712
82 0.234
18 0.623
38 0.127
0.5 0.337
36 0.186
2 1
54 0.366
27.2 0.490
40 0.215
32.7 0.480
0 0.933
88 1
5 0.772
35.5 0.320
39 0.478
20.3 0.914
16 0.154
s a low-density lipoprotein cholesterol level above 130 mg/dlAngi
us 
up (n
 9.1
8
4
2
2
4
2
0
2
0
6
0
3.3
5
1.6
6
4.5
5.7
6.9
2.7
0
ned a
d classification.
eart Association; PCI percutaneous coronary intervention.
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April 18, 2006:1522–9 Oral Rapamycin After Bare-Metal Stent Therapyere expressed as percentages. Changes in blood measure-
ents after rapamycin treatment were compared using the
aw data of the t test. Freedom from survival end points at
ollow-up were obtained using Kaplan-Meier curves and
ere compared by log-rank test. A multiple logistic regression
nalysis, backward stepwise method (Wald), was performed
o correlate angiographic binary restenosis with clinical and
ngiographic variables, including treatment groups. Statis-
ical significance was accepted for a value of p  0.05.
ESULTS
etween September 2003 and September 4, 2004, 100
atients were randomized, 50 patients in the control group
55 arteries and 59 lesions) and 50 patients in the oral
irolimus group (60 arteries and 66 lesions). A total of 132
tents were deployed, 61 in the control and 71 in the oral
irolimus group; a small stent size (2.5 mm) was deployed in
4.7% of the lesions. In the control group, 8 patients with
7 lesions in 13 vessels were treated. In the oral rapamycin
roup, 15 patients with 31 lesions in 25 vessels were treated.
The baseline demographic, clinical, and angiographic
haracteristics among both groups are described in Table 1;
reated diabetes was more frequent in the oral sirolimus
roup, p  0.054 (Fisher exact test). Hospital and 30-day
utcomes in both groups were similar (Table 2). During the
ourse of treatment with oral sirolimus, 26% of patients had
ide effects; however, none of them were major. The most
requent side effect was mouth ulceration (16%). Only two
atients (3.9%) discontinued treatment, at three and eight
ays after the first dose.
Table 2. Major Adverse Cardiac and Cardiova
Variable
Oral Sirolimus 
Stent Group (
In-hospital events (%)
Death 0
Myocardial infarction 4
Stroke 2
TLR 0
TVR 0
Target vessel failure 4
Any MACE 6
Out-of-hospital events (%)
Death 4
Myocardial infarction 0
Stroke 0
TLR 7.6
TVR 8.3
Target vessel failure 14
Any MACE 14
Cumulative to 367 days (%)
Death 4
Myocardial infarction 4
Stroke 2
TLR 7.6
TVR 8.3
Target vessel failure 18
Any MACE 20MACE  major adverse cardiovascular event; TLR  target lesioAfter the rapamycin treatment, during the first 30 days,
hite blood counts showed significant transient changes;
owever, severe leucopoenia was not seen. There was also
non-significant increase in triglycerides levels (Table 3).
linical follow-up. Hospital and follow-up results are
escribed in Table 2. One-year clinical follow-up (366 days)
as obtained in all patients (100%) in both groups; after
ospital discharge during the follow-up, there were two
eaths (4%) in the control group (both cardiac), whereas
wo patients in the oral sirolimus group (4%) died during
ollow-up (one because of colon cancer and the other after
n elective coronary bypass surgery). After hospital dis-
harge, there was no documented non-fatal myocardial
nfarction or stroke in either group.
The rate of clinically driven TLR or TVR was signifi-
antly lower (Fisher exact test) in the oral sirolimus com-
ared with the control group (Table 2). The TVR was 5 of
0 (8.3%) versus 21 of 55 (38%), respectively, p  0.001;
nd TLR was 5 of 66 (7.6%) versus 22 of 59 (37.2%),
espectively, p  0.001. Target vessel failure and MACEs
ere also improved with oral sirolimus therapy (p  0.009
nd p  0.018, respectively, Table 2). All surviving patients
nd those who did not have follow-up angiography were
symptomatic at 1 year of follow-up.
Figure 1 shows survival curves of freedom from TVR
Fig. 1A), freedom from TLR (Fig. 1B), and freedom from
ACEs (Fig. 1C) that have significantly better outcomes in
hose patients treated with oral sirolimus, with numbers that
epresent an 80% reduction of TLR and a 55% reduction of
ACEs compared with the control group.
r Events: In-Hospital and During Follow-Up
ndard
50)
Control Standard
Stent Group (n  50) p Value
0 —
2 0.986
2 —
0 —
0 —
2 0.986
2 0.638
4 —
0 —
0 —
37.2 0.001
35.2 0.001
40 0.006
40 0.006
4 —
2 0.986
2 —
37.2 0.001
38 0.001
44 0.009
44 0.018scula
Sta
n n revascularization; TVR  target vessel revascularization.
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Oral Rapamycin After Bare-Metal Stent Therapy April 18, 2006:1522–9ollow-up angiographic data. Baseline and follow-up an-
iographic data are shown in Table 4. Reference vessel size,
inimal luminal diameter before and after the procedure,
nd acute gain were similar in both groups.
Clinically driven or per-protocol follow-up angiography
t nine months was completed in 87% of the population (87
atients and 99 vessels). At nine months, the binary in-stent
estenosis rate per vessel was 12% for the rapamycin group
nd 34.6% for the control group (p  0.009). The in-
egment analysis showed a restenosis rate of 12% and 42.8%
or the rapamycin and control groups, respectively (p 
.001). As shown in Table 4, the use of oral rapamycin
educed the risk of binary restenosis by 65% within the stent
nd by 72% in the analysis segment. With the above
umbers, the power of our study to detect differences
etween groups for restenosis was 0.81 per patient and 0.94
er vessel, with a value of p  0.05. In the five patients in
he oral rapamycin group in whom restenosis developed, the
estenosis was diffuse but not proliferative or with total
cclusion. The restenosis pattern in the control group
howed that from 23 lesions with restenosis, only 3 were
mong 51% to 69%, 8 were between 69% to 80%, and 12
ere 80%, including 4 with almost complete closure
Thrombolysis In Myocardial Infarction [TIMI] flow grade
or 2). Thus, this finding (by quantitative coronary angiog-
aphy, severe restenosis in 87%) explains the rate of TLR in
he control group. With the oral therapy, in-stent late loss
as reduced from 1.41 mm in the control versus 0.73 mm in
he oral rapamycin group, and in-segment from 1.13 mm in
he control versus 0.66 mm in the oral rapamycin group,
eaning a reduction of 48% and 43% in-stent and in-
able 3. Oral Sirolimus Group at Baseline and at 21 Days:
aboratory Results and Adverse Reactions
Parameters Baseline 21 Days p Value
ed blood count 4.7  0.57 4.6  0.47 0.341
hite blood count 8,812  2,809 6,055  1,707 0.001
latelets 228,000  63,774 219,138  81,449 0.546
holesterol 173  39.4 173  34 1
riglycerides 100  50.9 126  56 0.056
lycemia 110.7  26.5 110.9  22.7 0.968
odium 141  3 141  3.6 1
hloride 105  3 104  3.54 0.131
irolimus in blood 13.46  4.5
Adverse Reactions
iarrhea 2 (4%)
omits 0
onstipation 0
astritis 0
outh ulceration 8 (16%)
ash 1 (2%)
ever 0
nteritis 1 (2%)
nsomnia 0
ngioedema 1 (2%)
iscontinued medication 2 (4%)
lobal 13 (26%)egment late loss, respectively. As mentioned previously, theigure 1. Kaplan-Meier curves showing event-free survival from target
esion revascularization (A), target vessel revascularization (B), and
ajor adverse cardiovascular events (C) for the global follow-up. The p
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oss in the control group.
Multivariate analysis showed that randomization to the
ontrol group was the only independent predictor of reste-
osis (odds ratio [OR] 6.01, 95% confidence interval 2.19 to
6.46, p  0.0001). As shown in Table 4, compared with
he control group, patients who received oral rapamycin had
significantly smaller amount of late loss (0.66 mm in the
irolimus group vs. 1.13 mm in the control group, p 0.0002),
esulting in greater luminal dimension and a smaller degree
f stenosis at follow-up. The relative reduction in the risk of
estenosis among patients who received oral rapamycin was
ndependent of diabetes mellitus status, vessel location, and
he length and diameter of the lesion or stent.
ISCUSSION
his prospective, randomized, controlled trial in patients
ith de novo lesions showed a significant reduction of
ngiographic binary restenosis and late loss when patients
ere allocated to the oral sirolimus group, and both end
oints were determined by blinded operators. Clinical safety
nd efficacy parameters of restenosis, such as TVR, TLR,
nd MACEs at follow-up were also significantly improved
Table 4. Results of Quantitative Coronary Ang
Variable*
Oral Sirolim
Stent Gr
Before procedure
Reference diameter (mm) 2.96
MLD (mm) 1.03
Diameter stenosis (%) 66.5
After procedure
Reference diameter (mm) 3.02
In-stent MLD (mm) 2.99
In-segment MLD (mm) 2.7
In-stent diameter stenosis (%) 4.8
In-segment diameter stenosis (%) 11.7
Follow-up (285  54 days)
Reference diameter (mm) 2.95
In-stent MLD (mm) 2.26
In-segment MLD (mm) 2.04
In-stent diameter stenosis (%) 19.6
In-segment diameter stenosis (%) 32.7
In-stent late loss (mm) 0.73
In-segment late loss (mm) 0.66
Lesion length (mm) 13.35
Stent length (mm) 15.7
In-segment acute gain (mm)† 1.68
In-segment net gain (mm)‡ 0.97
In-segment restenosis (%)§
Per patient (n  87) 11.
Per vessel (n  99) 1
In-stent restenosis (%)§
Per patient (n  87) 11.
Per vessel (n  99) 1
*Late luminal loss was defined as the difference between the m
of the stent and the MLD at mean 285 days. †Acute ga
immediately after the placement of the stent. ‡Net gain wa
procedure and the MLD at 285 days. §Restenosis was defin
285-day follow-up angiogram.ith oral sirolimus therapy. RThe population sample analyzed in the present study
epresents a relatively high-risk population involving B2/C
esions (approximately 70%), small vessels (44.7%), and
esions longer than 18 mm (53%). Also, overlapping (7%)
nd multiple stent implantations per treated vessel (17%)
ere also allowed in the study. Finally, despite the short
eriod of oral administration of the drug, minor side effects
ere present in 26% of patients.
Several pre-clinical studies supported the use of systemic
dministration of rapamycin or its analog everolimus in
educing smooth muscle cell proliferation (20–25). The
nti-inflammatory and antiproliferative effects of rapamycin
as based on its ability to inhibits the TOR kinase (target of
apamycin), an essential component in the pathway of the
ell cycle progression (20–24). Drug-eluting stents have
een extensity studied in several randomized studies (10–
7); however, their long-term safety data are not well
stablished (18,19).
Systemic use of oral sirolimus in patients undergoing PCI
rocedures has been recently tested. One randomized trial
n patients with in-stent restenosis (29) showed a significant
eduction of restenosis and late loss in the high-oral-
irolimus dose group. The Oral Rapamune to Inhibit
aphy
Standard
n  50)
Control Standard
Stent Group (n  50) p Value
.64 2.91  0.41 0.47
.43 0.98  0.48 0.571
2.2 65.68  14.66 0.755
.44 2.94  0.36 0.27
.48 2.92  0.50 0.46
.37 2.62  0.38 0.171
0.7 4.7  10.6 0.96
.6 11.3  7.27 0.726
.53 2.87  0.45 0.35
.55 1.51  0.65 0.0002
.70 1.47  0.76 0.0002
7.7 54  20.8 0.0002
0.15 55.76  25.01 0.001
.40 1.41  0.67 0.0002
.59 1.13  0.72 0.0002
.33 12.79  4.28 0.144
.62 16  2.78 0.149
.43 1.76  0.49 0.371
.62 0.49  0.88 0.007
3) 45.4 (20/44) 0.001
0) 42.8 (21/49) 0.001
3) 36.4 (16/44) 0.011
0) 34.6 (17/49) 0.009
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ohort of 60 patients treated with low and high oral doses of
irolimus (30), and when 2 mg/day as a maintenance dose
as used, only minor side effects were reported.
We previously performed two observational studies
27,31) showing that a sirolimus blood concentration of 8
g/ml was associated with a single-digit restenosis rate and
ower late loss. In the present randomized study, the
irolimus oral administration scheme was different than we
reviously reported (27,31): the bolus was given two h
efore intervention, and the daily dose was 3 mg instead 2
g and was used only for 14 days. It is not clear when would
e the ideal moment to start oral sirolimus treatment; in one
tudy (29) of patients with in-stent restenosis, the oral
irolimus loading dose was administrated two days before
he procedure. This was supported by the concept that the
mmunosuppressive effects of sirolimus achieved optimal
evels after 4 days of treatment, and that perhaps, with a
igh-risk population for restenosis such as patients with
n-stent restenosis, a pre-intervention loading dose would
btain better results.
Finally, drug-eluting stents have been associated with a
ignificant reduction of restenosis and late loss compared
ith bare-metal stents; in fact, late loss during the first year
f follow-up showed only a minor increase in minimal
uminal diameter with drug-eluting stent therapy, and those
umbers (13,14) are lower than the results presented here,
eaning that local therapy achieved high immunosuppres-
ive effects.
In conclusion, this was the first randomized study using
ral rapamycin in patients with de novo lesions treated with
oronary bare metal stent therapy. We report a significant
eduction of angiographic and clinical parameters of reste-
osis, suggesting that this treatment may be a cost-effective
lternative (33) to drug-eluting stent therapy in a selected
roup of patients, such as those at moderate risk of
estenosis, with a reference vessel size 2.5 mm, without
iabetes, and unsuitable for long-term antiplatelet therapy.
tudy limitations. First, the restenosis and late loss of the
are metal stent therapy in the control group was slightly
igher than historical records reported with other stent
esigns, and the patient population of the trial could be in
art responsible for the high restenosis rate. However, it is
ossible that these parameters would be lower with different
tent designs. Nevertheless, in the drug-eluting stent era,
tent binary restenosis in the control groups was similar to
hat we are reporting here in the control group (12–14).
urthermore, it is very important to emphasize that we used
he same stent design in both groups, and these findings are
n favor of the immunosuppressive effects of oral rapamycin.
oth restenosis and late loss could be lower if we associated
he oral therapy with a third generation of bare metal stent
esign. However, if a much lower restenosis rate were seen
n the control group, such as that seen with the third
eneration of bare metal stents, the ability to show a
1ifference might not have been possible with the sample size
hosen in our study.
Second, we conducted an angiographic follow-up at nine
onths, and it is unknown whether these findings will be
aintained during more prolonged follow-up. Furthermore,
he optimal dosing, the need for pre-treatment, and the
uration of the oral therapy have not been determined by
his study. Minor side effects were present in 26% of the
atients, and these numbers could be underestimated be-
ause of the sample size. Finally, more complex subsets of
esions were not analyzed by this study, and they would need
urther investigation.
eprint requests and correspondence: Dr. Alfredo E. Rodriguez,
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